Ticker Details
Veru Inc. Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.
IPO Date:	February 25, 1999
Sector:	Consumer Staples
Industry:	Personal Products
Market Cap:	$45.01M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.19 | 4.34%
Avg Daily Range (30 D):	$0.09 | 3.82%
Avg Daily Range (90 D):	$0.11 | 4.21%

Institutional Daily Volume
Avg Daily Volume:	2.11M
Avg Daily Volume (30 D):	.24M
Avg Daily Volume (90 D):	1.37M

Trade Size
Avg Trade Size (Sh.):	209
Avg Trade Size (Sh.) (30 D):	138
Avg Trade Size (Sh.) (90 D):	145

Institutional Trades
Total Institutional Trades:	667
Avg Institutional Trade:	$1.41M
Avg Institutional Trade (30 D):	$.5M
Avg Institutional Trade (90 D):	$.88M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$1.71M
Avg Closing Trade (30 D):	$.5M
Avg Closing Trade (90 D):	$.5M
Avg Closing Volume:	30.11K

News

Dec 31, 2024 @ 4:29 PM Veru Sells FC2 Condom Business For $18 Million, Fo... Source: Lekha Gupta

Dec 31, 2024 @ 1:30 PM Veru Announces the Sale of the FC2 Female CondomÂ... Source: N/A

Oct 3, 2024 @ 12:30 PM Sexual Wellness Market to Witness 4.7% CAGR by 203... Source: Globe Newswire

Jul 2, 2024 @ 12:30 PM Veru to Participate in the Leerink Therapeutics Fo... Source: Veru Inc.

Jun 24, 2024 @ 12:30 PM Veru Announces Safety and Body Composition Data fr... Source: Veru Inc.

Financials
	TTM	Q3 2026	Q2 2026
Basic EPS	$-.57	$-.3	$-.12
Diluted EPS
Revenue	$8.63M	$M	$M
Gross Profit
Net Income / Loss	$-6.56M	$-6.99M	$-2.74M
Operating Income / Loss	$-19.19M	$-7.71M	$-7.22M
Cost of Revenue
Net Cash Flow	$8.91M	$-3.72M	$11.8M
PE Ratio

Splits
Aug 11, 2025	1:10